| 4.27 0.03 (0.71%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.35 | 1-year : | 6.25 |
| Resists | First : | 4.58 | Second : | 5.35 |
| Pivot price | 4.08  |
|||
| Supports | First : | 3.66 | Second : | 3.09 |
| MAs | MA(5) : | 4.28 |
MA(20) : | 4 |
| MA(100) : | 3.04 |
MA(250) : | 2.76 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 77.9 |
D(3) : | 82.7 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 5.05 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NRXP ] has closed below upper band by 26.4%. Bollinger Bands are 11.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.42 | 4.42 - 4.44 |
| Low: | 4.02 - 4.04 | 4.04 - 4.06 |
| Close: | 4.23 - 4.27 | 4.27 - 4.3 |
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Thu, 16 Jul 2026
Market Sentiment Around Loss-Making NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) - simplywall.st
Wed, 15 Jul 2026
Is NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation? - Yahoo Finance
Fri, 10 Jul 2026
NRXP Stock Price, Quote & Chart - ChartMill
Thu, 25 Jun 2026
HOPE starts first FDA-cleared TMS treatments in Florida clinics - Stock Titan
Fri, 05 Jun 2026
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by - GlobeNewswire
Tue, 02 Jun 2026
Biotech NRx to sell new shares to fund growth and operations - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 17.5 (%) |
| Shares Short | 5,400 (K) |
| Shares Short P.Month | 4,980 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | 0 % |
| Operating Margin | -444.6 % |
| Return on Assets (ttm) | -110.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -4.11 |
| PEG Ratio | 0 |
| Price to Book value | -10.42 |
| Price to Sales | 79.8 |
| Price to Cash Flow | -12.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|